(Q42912913)

11 November 2017

title

Maternal and nenonatal tenofovir and emtricitabine to prevent vertical transmission of HIV-1: tolerance and resistance (English)

1 reference

11 November 2017

0 references

1 reference

vertical transmission

1 reference

1 reference

13

François Dabis

1 reference

11 November 2017

6

Christine Rouzioux

1 reference

11 November 2017

11

Glenda Gray

1 reference

11 November 2017

4

Eric Nerrienet

1 reference

11 November 2017

3

Marie-Laure Chaix

1 reference

11 November 2017

2

Elise Arrivé

1 reference

11 November 2017

5

Stéphane Blanche

1 reference

11 November 2017

7

Divine Avit

1 reference

TEmAA ANRS 12109 Study Group

11 November 2017

1

object named as

TEmAA ANRS 12109 Study Group

1 reference

11 November 2017

8

Leang Sim Kruy

1 reference

11 November 2017

James McIntyre

9

1 reference

11 November 2017

Leakhena Say

10

1 reference

11 November 2017

Didier K. Ekouévi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20827166

9 July 2024

language of work or name

English

0 references

publication date

1 October 2010

1 reference

11 November 2017

23 October 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20827166

full work available at URL

9 July 2024

https://journals.lww.com/00002030-201010230-00007

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

9 July 2024

1 reference

11 November 2017

volume

24

1 reference

11 November 2017

issue

16

1 reference

11 November 2017

page(s)

2481-2488

1 reference

Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study

11 November 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT.

9 July 2024

2

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda

9 July 2024

3

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers

9 July 2024

4

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa

9 July 2024

5

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience

9 July 2024

6

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

9 July 2024

7

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Response to antiretroviral therapy after a single, peripartum dose of nevirapine

9 July 2024

8

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study

9 July 2024

9

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia

9 July 2024

10

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial

9 July 2024

11

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine

9 July 2024

12

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial

9 July 2024

13

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire

9 July 2024

14

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention

9 July 2024

15

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission

9 July 2024

16

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

9 July 2024

17

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.

9 July 2024

18

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).

9 July 2024

19

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates

9 July 2024

20

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting

9 July 2024

21

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance

9 July 2024

23

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children

9 July 2024

24

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection

9 July 2024

25

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.

9 July 2024

26

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Adverse effects of tenofovir use in HIV-infected pregnant women and their infants

9 July 2024

27

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir

9 July 2024

28

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Values for urinary beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in normal healthy infants

9 July 2024

29

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis

9 July 2024

30

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine

9 July 2024

31

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.

9 July 2024

32

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine

9 July 2024

33

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.

9 July 2024

34

1 reference

https://api.crossref.org/works/10.1097/QAD.0B013E32833E1659

9 July 2024

Identifiers

1 reference

11 November 2017

1 reference